KR102705724B1 - 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸 - Google Patents

신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸 Download PDF

Info

Publication number
KR102705724B1
KR102705724B1 KR1020237022665A KR20237022665A KR102705724B1 KR 102705724 B1 KR102705724 B1 KR 102705724B1 KR 1020237022665 A KR1020237022665 A KR 1020237022665A KR 20237022665 A KR20237022665 A KR 20237022665A KR 102705724 B1 KR102705724 B1 KR 102705724B1
Authority
KR
South Korea
Prior art keywords
optionally substituted
mixture
compound
pyrazol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237022665A
Other languages
English (en)
Korean (ko)
Other versions
KR20230107407A (ko
Inventor
앤서니 에이. 에스트라다
지안웬 에이. 펭
조셉 피. 리시카토스
자카리 케이. 스위니
자비에르 드 비센테 피달고
Original Assignee
데날리 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데날리 테라퓨틱스 인크. filed Critical 데날리 테라퓨틱스 인크.
Priority to KR1020247029993A priority Critical patent/KR102843750B1/ko
Publication of KR20230107407A publication Critical patent/KR20230107407A/ko
Application granted granted Critical
Publication of KR102705724B1 publication Critical patent/KR102705724B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
KR1020237022665A 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸 Active KR102705724B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247029993A KR102843750B1 (ko) 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201662350876P 2016-06-16 2016-06-16
US62/350,876 2016-06-16
US201662417151P 2016-11-03 2016-11-03
US62/417,151 2016-11-03
US201762476581P 2017-03-24 2017-03-24
US62/476,581 2017-03-24
US201762510711P 2017-05-24 2017-05-24
US62/510,711 2017-05-24
PCT/US2017/037782 WO2017218843A1 (en) 2016-06-16 2017-06-15 Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
KR1020197000749A KR102553188B1 (ko) 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197000749A Division KR102553188B1 (ko) 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029993A Division KR102843750B1 (ko) 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸

Publications (2)

Publication Number Publication Date
KR20230107407A KR20230107407A (ko) 2023-07-14
KR102705724B1 true KR102705724B1 (ko) 2024-09-12

Family

ID=59216078

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197000749A Active KR102553188B1 (ko) 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸
KR1020237022665A Active KR102705724B1 (ko) 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸
KR1020247029993A Active KR102843750B1 (ko) 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197000749A Active KR102553188B1 (ko) 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247029993A Active KR102843750B1 (ko) 2016-06-16 2017-06-15 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸

Country Status (37)

Country Link
US (7) US20170362206A1 (enExample)
EP (3) EP3472153B1 (enExample)
JP (1) JP7004459B2 (enExample)
KR (3) KR102553188B1 (enExample)
CN (2) CN109311857B (enExample)
AU (3) AU2017286653B2 (enExample)
CA (1) CA3025672A1 (enExample)
CL (1) CL2018003597A1 (enExample)
CO (1) CO2018013585A2 (enExample)
CR (2) CR20220182A (enExample)
CU (1) CU24605B1 (enExample)
CY (1) CY1124789T1 (enExample)
DK (1) DK3998261T3 (enExample)
DO (3) DOP2018000285A (enExample)
EC (1) ECSP18092481A (enExample)
ES (2) ES3036953T3 (enExample)
HR (1) HRP20211923T1 (enExample)
HU (1) HUE056678T2 (enExample)
IL (3) IL299415B2 (enExample)
JO (1) JOP20180113B1 (enExample)
LT (1) LT3472153T (enExample)
MD (1) MD3472153T2 (enExample)
MX (3) MX392230B (enExample)
PE (2) PE20190395A1 (enExample)
PH (1) PH12018502427A1 (enExample)
PL (1) PL3472153T3 (enExample)
PT (1) PT3472153T (enExample)
RS (1) RS62868B1 (enExample)
SA (2) SA521430638B1 (enExample)
SG (2) SG11201810579YA (enExample)
SI (1) SI3472153T1 (enExample)
SM (1) SMT202100699T1 (enExample)
TN (1) TN2018000422A1 (enExample)
TW (1) TWI786049B (enExample)
UA (1) UA126231C2 (enExample)
WO (1) WO2017218843A1 (enExample)
ZA (1) ZA201900229B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
AU2018372180B2 (en) 2017-11-21 2023-08-17 Denali Therapeutics Inc. Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
CN112088003B (zh) 2017-12-20 2023-10-13 戴纳立制药公司 制备嘧啶基-4-氨基吡唑化合物的工艺
KR20190131981A (ko) * 2018-05-18 2019-11-27 재단법인 대구경북첨단의료산업진흥재단 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물
AR118641A1 (es) * 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos
MX2021014705A (es) * 2019-05-31 2022-04-06 Denali Therapeutics Inc Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento.
EP3769768A1 (en) 2019-07-23 2021-01-27 Consejo Superior de Investigaciones Cientificas (CSIC) Compounds useful for the treatment of parkinson s disease
UY38934A (es) * 2019-10-29 2021-05-31 Biogen Ma Inc Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica
KR102342803B1 (ko) 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
EP4129994A4 (en) 2020-03-23 2024-04-24 Whan In Pharmaceutical Co., Ltd. Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
CA3191189A1 (en) * 2020-10-07 2022-04-14 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders
CA3197034A1 (en) * 2020-10-29 2022-05-05 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
CA3217230A1 (en) * 2021-04-30 2022-11-03 Denali Therapeutics Inc. Methods for treating and monitoring parkinson's disease
US11780851B2 (en) 2021-10-27 2023-10-10 H. Lundbeck A/S LRRK2 inhibitors
MX2024007383A (es) 2021-12-15 2024-08-28 Whan In Pharmaceutical Co Ltd Derivado de pirimidina macrocíclica, método para preparar el mismo y composición farmacéutica para prevención o tratamiento de una enfermedad neurodegenerativa que contiene el mismo como ingrediente activo.
CN117624185B (zh) * 2022-08-23 2025-12-05 长春金赛药业有限责任公司 Lrrk2抑制剂化合物、药物组合物及其制备方法和应用
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors
EP4612141A1 (en) 2022-11-03 2025-09-10 Denali Therapeutics Inc. Solid and co-crystal forms of a pyrimidine triazole compound
CN115894456A (zh) * 2022-11-13 2023-04-04 药康众拓(江苏)医药科技有限公司 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途
KR20250102043A (ko) 2022-11-22 2025-07-04 데날리 테라퓨틱스 인크. 피리미딘 아미노피라졸 화합물의 제조 방법 및 중간체
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用
CN119968373A (zh) * 2023-09-07 2025-05-09 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法
CN118878521B (zh) * 2024-09-26 2025-02-14 苏州美诺医药科技有限公司 一种lrrk2抑制剂的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062783A1 (en) 2010-11-10 2012-05-18 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators
WO2013164321A1 (en) 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1058549A4 (en) 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
WO2003076658A2 (en) 2002-03-08 2003-09-18 Decode Genetics Ehf. A susceptibility gene for late-onset idiopathic parkinson's disease
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
JP2009532375A (ja) 2006-03-30 2009-09-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
KR20090019848A (ko) 2006-06-20 2009-02-25 노파르티스 아게 알쯔하이머 병의 진행에 대한 생체마커
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN101679299A (zh) 2007-04-19 2010-03-24 诺瓦提斯公司 作为代谢型谷氨酸受体-5调节剂的烟酸衍生物
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
CN101687852A (zh) 2007-05-24 2010-03-31 沃泰克斯药物股份有限公司 可用作激酶抑制剂的噻唑类和吡唑类化合物
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
WO2011060295A1 (en) 2009-11-13 2011-05-19 Genosco Kinase inhibitors
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
MX2012014158A (es) 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
EP2632260A4 (en) 2010-10-29 2015-06-17 Merck Sharp & Dohme LEUCINREICH REPEAT KINASE ENZYME ACTIVITY
MX2013005801A (es) 2010-11-30 2013-07-17 Genentech Inc Ensayos y biomarcadores para lrrk2.
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
AU2012288892B2 (en) 2011-07-28 2016-04-21 Cellzome Limited Heterocyclyl pyrimidine analogues as JAK inhibitors
CN103814030A (zh) 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
EP2807152B1 (en) 2011-11-29 2017-07-19 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
PL2785711T3 (pl) 2011-11-29 2017-01-31 F.Hoffmann-La Roche Ag Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona
CN106349234A (zh) 2011-11-29 2017-01-25 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
CN104093426B (zh) 2011-11-30 2019-06-28 健泰科生物技术公司 用于lrrk2的正电子发射体层摄影(pet)成像的氟-18和碳-11标记的放射性配体
WO2013126283A1 (en) 2012-02-20 2013-08-29 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
PL2820009T3 (pl) 2012-03-01 2018-09-28 Array Biopharma, Inc. Inhibitory kinaz serynowo/treoninowych
RU2637948C2 (ru) * 2012-05-03 2017-12-08 Дженентек, Инк. Производные пиразоламинопиримидина в качестве модуляторов обогащенной лейциновыми повторами киназы 2 (lrrk2) для применения при лечении болезни паркинсона
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2014116772A2 (en) 2013-01-25 2014-07-31 Bristol-Myers Squibb Company Squaric derivatives for the treatment of hepatitis c
EP3010908A1 (en) 2013-02-20 2016-04-27 E. I. du Pont de Nemours and Company Fungicidal pyrazoles
WO2014135245A1 (en) 2013-03-05 2014-09-12 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
WO2014150981A1 (en) 2013-03-15 2014-09-25 Elan Pharmaceuticals, Llc Inhibitors of lrrk2 kinase activity
US9676792B2 (en) 2013-03-15 2017-06-13 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
SMT201800501T1 (it) 2013-05-10 2018-11-09 Karus Therapeutics Ltd Nuovi inibitori di istone deacetilasi
KR20160106622A (ko) 2014-01-29 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
WO2015131005A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
WO2015148868A1 (en) 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP6684780B2 (ja) 2014-08-25 2020-04-22 ソーク インスティテュート フォー バイオロジカル スタディーズ 新規ｕｌｋ１阻害剤およびそれを使用する方法
CN105461694B (zh) 2014-09-27 2019-05-24 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
PL3227297T3 (pl) 2014-12-05 2021-10-25 Array Biopharma, Inc. 4,6 podstawione-pyrazolo[1,5-a]pirazyny jako inhibitory kinaz janusowych
EP3271336A1 (en) 2015-03-19 2018-01-24 E. I. du Pont de Nemours and Company Fungicidal pyrazoles
JP2018135268A (ja) 2015-06-05 2018-08-30 大日本住友製薬株式会社 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
WO2017087282A1 (en) 2015-11-18 2017-05-26 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
WO2017100703A1 (en) 2015-12-10 2017-06-15 Colin Combs Ems analogues of lyn/src-tyrosine kinase inhibitors
CN108934162A (zh) 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
EA201891620A1 (ru) * 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
WO2018217946A1 (en) 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062783A1 (en) 2010-11-10 2012-05-18 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators
WO2013164321A1 (en) 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Also Published As

Publication number Publication date
US20180208582A1 (en) 2018-07-26
SG10201912632YA (en) 2020-02-27
EP3472153B1 (en) 2021-09-22
IL299415B1 (en) 2025-05-01
PL3472153T3 (pl) 2022-02-07
EP3472153A1 (en) 2019-04-24
CN114315819A (zh) 2022-04-12
CL2018003597A1 (es) 2019-02-15
SG11201810579YA (en) 2018-12-28
JP7004459B2 (ja) 2022-02-10
US20250034119A1 (en) 2025-01-30
EP4635570A2 (en) 2025-10-22
JOP20180113B1 (ar) 2022-03-14
CR20180592A (es) 2019-03-05
MX2018015630A (es) 2019-04-11
CY1124789T1 (el) 2022-11-25
MX2022005610A (es) 2022-06-23
JOP20180113A1 (ar) 2019-01-30
US20170362206A1 (en) 2017-12-21
CO2018013585A2 (es) 2019-01-18
DOP2023000077A (es) 2023-05-31
US20220135546A1 (en) 2022-05-05
KR20240137707A (ko) 2024-09-20
US10590114B2 (en) 2020-03-17
IL299415A (en) 2023-02-01
PE20240221A1 (es) 2024-02-16
CN109311857A (zh) 2019-02-05
EP3998261B1 (en) 2025-05-07
ECSP18092481A (es) 2018-12-31
KR102843750B1 (ko) 2025-08-07
TW201835069A (zh) 2018-10-01
ES2900368T3 (es) 2022-03-16
PT3472153T (pt) 2021-12-31
DOP2018000285A (es) 2019-01-15
IL263484B1 (en) 2023-10-01
AU2017286653B2 (en) 2021-11-04
IL263484B2 (en) 2024-02-01
WO2017218843A1 (en) 2017-12-21
IL299412B1 (en) 2025-01-01
CA3025672A1 (en) 2017-12-21
AU2024204621A1 (en) 2024-07-18
ZA201900229B (en) 2022-10-26
IL299412B2 (en) 2025-05-01
TWI786049B (zh) 2022-12-11
US11591316B2 (en) 2023-02-28
TN2018000422A1 (en) 2020-06-15
AU2022202372B2 (en) 2024-04-04
EP3998261A1 (en) 2022-05-18
DOP2022000088A (es) 2022-06-15
RS62868B1 (sr) 2022-02-28
PH12018502427A1 (en) 2019-09-30
MD3472153T2 (ro) 2022-03-31
JP2019521984A (ja) 2019-08-08
IL263484A (en) 2019-01-31
ES3036953T3 (en) 2025-09-26
US11111235B2 (en) 2021-09-07
CN109311857B (zh) 2021-11-12
US20180051009A1 (en) 2018-02-22
BR112018075569A2 (pt) 2019-03-19
LT3472153T (lt) 2021-12-27
US9932325B2 (en) 2018-04-03
CU24605B1 (es) 2022-06-06
DK3998261T3 (da) 2025-08-18
HRP20211923T1 (hr) 2022-03-04
AU2022202372A1 (en) 2022-04-28
SA518400660B1 (ar) 2023-06-04
MX392230B (es) 2025-03-21
SI3472153T1 (sl) 2022-01-31
US11834439B2 (en) 2023-12-05
US20210002260A1 (en) 2021-01-07
KR102553188B1 (ko) 2023-07-11
HUE056678T2 (hu) 2022-02-28
CU20180152A7 (es) 2019-09-04
US20230227436A1 (en) 2023-07-20
AU2017286653A1 (en) 2018-12-20
NZ748936A (en) 2024-12-20
CR20220182A (es) 2022-06-15
UA126231C2 (uk) 2022-09-07
MX2021010304A (es) 2021-10-13
SMT202100699T1 (it) 2022-01-10
KR20190018676A (ko) 2019-02-25
SA521430638B1 (ar) 2023-07-12
PE20190395A1 (es) 2019-03-13
IL299412A (en) 2023-02-01
IL299415B2 (en) 2025-09-01
KR20230107407A (ko) 2023-07-14

Similar Documents

Publication Publication Date Title
KR102705724B1 (ko) 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸
HK40074923A (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
HK40074923B (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
HK40007576B (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
OA19864A (en) Compounds, compositions, and methods.
BR122021017711B1 (pt) Compostos inibidores de lrrk2, composição farmacêutica que os compreendem, usos dos compostos e processos para preparação dos compostos

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601